Home
6494 All Specialties
1559 Arthroplasty
641 Shoulder & Elbow
577 Osteoarthritis
575 Physical Therapy & Rehab
570 Spine
552 Sports Medicine
543 Trauma
412 General Orthopaedics
345 Foot & Ankle
295 Hand & Wrist
198 Cannabis
88 Pediatric Orthopaedics
79 Metabolic Disorders
29 Peri-Operative
29 Tumour
2 Evidence Based Medicine

Conference Reports

Summaries of the best evidence presented at major orthopaedic conferences around the world.

Exclusive Interviews

Original authors are interviewed to verify the veracity of the ACE Report and provide additional information regarding the study’s findings and methodology.

PeerView

Features the top trending OE Content from your network over the past 30 days.

OE Originals
OE Insights
Videos
OE Plus
148 COVID 19 Resource Center
7 Ace Reviews
1 OE Recommends
6 OE PeerView
78 OE Ideas
24 OE World Tour
63 OE Perspectives
48 Conference ACE Reports
159 Exclusive Interviews
CME

To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:20 Issue:1 Number:4 ISSN#:2564-2537
RCT
ACE Report #13409
Ace Report Cover General Orthopaedics

No Clinical Benefit of LY-CoV555 Antibodies Plus Remdesivir in Hospitalized COVID-19 Patients

How to Cite

OrthoEvidence. No Clinical Benefit of LY-CoV555 Antibodies Plus Remdesivir in Hospitalized COVID-19 Patients. ACE Report. 2021;20(1):4. Available from: https://myorthoevidence.com/AceReport/Report/13409

Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

N Engl J Med. 2021 Mar 11;384(10): 905-914.

Contributing Authors:
Group ACTIV-3/TICO LY-CoV555 Study JD Lundgren B Grund CE Barkauskas TL Holland RL Gottlieb U Sandkovsky SM Brown KU Knowlton WH Self DC Files MK Jain T Benfield ME Bowdish BG Leshnower JV Baker JU Jensen EM Gardner AA Ginde ES Harris IS Johansen N Markowitz MA Matthay L √òstergaard CC Chang VJ Davey A Goodman ES Higgs DD Murray TA Murray R Paredes MKB Parmar AN Phillips C Reilly S Sharma RL Dewar M Teitelbaum D Wentworth H Cao P Klekotka AG Babiker AC Gelijns VL Kan MN Polizzotto BT Thompson HC Lane JD Neaton

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

Three hundred and fourteen hospitalized patients with COVID-19 were randomized to receive a single intravenous infusion of LY-CoV555 antibody therapy (n=163) or placebo (n=151) for the improvement of recovery and reduction of adverse events. The primary outcomes of interest was sustained recovery (discharged home and remaining at home for at lest 14 days) and a composite safety outcome of death, s...

To view the full content, login to your account,
or start your 30-day FREE Trial today.

FREE TRIAL Forgot Password?

Explore some of our unlocked ACE Reports below!

 Treatment of osteoarthritis: A role for education programmes?
The prevalence of intimate partner violence in women presenting to orthopaedic clinics
Osteoporosis Choice decision aid improves treatment experience of clinicians and patients
Protein-Rich nutritional supplementation shows limited efficacy in elderly hip fractures
Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE
For Reprints and Permissions, click here

Please Login or Join to leave comments.